Oaktree Acquisition Corp. III Life Sciences’ (NASDAQ:OACCU) Lock-Up Period To End Tomorrow

Oaktree Acquisition Corp. III Life Sciences’ (NASDAQ:OACCU) lock-up period will expire on Tuesday, April 22nd. Oaktree Acquisition Corp. III Life Sciences had issued 17,500,000 shares in its IPO on October 24th. The total size of the offering was $175,000,000 based on an initial share price of $10.00. After the expiration of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Oaktree Acquisition Corp. III Life Sciences Stock Performance

Shares of Oaktree Acquisition Corp. III Life Sciences stock opened at $10.31 on Monday. The company’s 50-day simple moving average is $10.26. Oaktree Acquisition Corp. III Life Sciences has a one year low of $9.99 and a one year high of $10.60.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of OACCU. Rangeley Capital LLC acquired a new stake in Oaktree Acquisition Corp. III Life Sciences in the fourth quarter worth $101,000. Athos Capital Ltd bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth about $507,000. Kepos Capital LP acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $709,000. Affinity Asset Advisors LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $2,538,000. Finally, Whitebox Advisors LLC bought a new stake in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $2,532,000.

About Oaktree Acquisition Corp. III Life Sciences

We are a newly organized blank check company incorporated on June 28, 2024, as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination.